Compared to paclitaxel, nab‐paclitaxel may enhance antitumor activity by selective targeting of HNSCC cells with upregulated macropinocytosis due to constitutive hyper‐activation of the EGFR/RAS/PIK3CA signaling pathways [7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.